Keeping Track: A Fresh Wave Of Approvals
Executive Summary
The latest drug development news and highlights from our US FDA Performance Tracker.
You may also be interested in...
Expanded Lung Cancer Claim For Lilly’s Cyramza Faces US FDA Scrutiny
Oncologic Drugs Advisory Committee will consider whether a statistically significant benefit on progression-free survival, but no survival advantage, is enough to secure a first-line lung cancer indication for ramucirumab.
XLH Patient Meeting Showcases Value Of Post-Approval Feedback To US FDA
X-Linked Hypophosphatemia patient feedback meeting follows recent approval of Ultragenyx’ Crysvita. Like an SMA meeting in 2017, it showed how post-approval meetings can help sustain momentum in a new class.
Keeping Track: US FDA Approves Novel Tetracyclines Nuzyra And Seysara; Hemlibra Indication Expands
The latest drug development news and highlights from our US FDA Performance Tracker.